Stay updated with breaking news from Nasdaq Ortx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Orchard Therapeutics (NASDAQ:ORTX – Get Rating) had its target price raised by Cantor Fitzgerald to $15.00 in a research report released on Tuesday morning, The Fly reports. They currently have an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($6.25) EPS. Separately, Oppenheimer increased their target price […]
OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) ...
All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up Four out of five patients...
Libmeldy® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe First case of MLD confirmed from...
Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST...